COPD is a disease associated with chronic inflammation of the airways and lung parenchyma, characterized by persistent lung injury, activates a regulatory mechanism that downgrades the immune response, including PD-L1/PD-1 [23], and thus opening a therapeutic window among patients with COPD who develop lung cancer. This evidence concerns the gene CD274 and lung carcinoma.